Arovella Secures Option to License Cell Receptors Targeting Solid Tumours From US College

MT Newswires Live
05/05

Arovella Therapeutics (ASX:ALA) secured an exclusive six-month option to license chimeric antigen receptors from the Baylor College of Medicine in Texas, according to a Monday filing with the Australian bourse.

The option covers two chimeric antigen receptors (CARs) targeting GD2 and GPC3, clinically validated targets in cancers such as neuroblastoma, glioma, and hepatocellular carcinoma, the filing said.

If exercised, the license would allow Arovella to incorporate the CARs and additional enhancements into its allogeneic CAR-iNKT cell therapies, the filing added.

No upfront fee was paid for the option. During the option period, Baylor is restricted

from offering the technologies to other parties in the same field, the company said.

The parties intend to negotiate a definitive licence agreement if Arovella proceeds, the company added.

Shares of Arovella Therapeutics rose past 2% in recent Monday trade.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10